April 17, 2019

Deal Snapshot: Regeneron & Alnylam Pharmaceuticals

Median deal values by quarter

  • Upfront: USD 400M
  • Equity: USD 400M
  • Milestones: USD 200M
  • R&D Funding: USD 30M
  • Total Deal Value: USD 1030M
  • Royalties: Yes (no further details disclosed)

Regeneron Key BD Contacts

Regeneron Deal Activity by Therapeutic Area (Last 3 Years)

Recent deal activity by disease area

Recent In-Licensing Deals and Acquisitions:

Regeneron Pipeline Composition

Pipeline composition, disease areas

Regeneron Lead Ophthalmology Assets

Asset Indication Stage
Aflibercept Non-proliferative diabetic retinopathy without DME Phase III, Phase II/III

Business profiles tailored to your asset.